Valuation: Talphera, Inc.

Market Cap 5.24Cr 4.7Cr 4.3Cr 3.92Cr 7.39Cr 492.81Cr 7.62Cr 52Cr 21Cr 262.95Cr 20Cr 19Cr 830.11Cr P/E 2026 *
-4.66x
P/E 2027 * -4.64x
Enterprise Value 5.24Cr 4.7Cr 4.3Cr 3.92Cr 7.39Cr 492.81Cr 7.62Cr 52Cr 21Cr 262.95Cr 20Cr 19Cr 830.11Cr EV / Sales 2026 *
-
EV / Sales 2027 * 117x
Free-Float
78.59%
Yield 2026 *
-
Yield 2027 * -
1 day+3.47%
1 week+0.97%
Current month+0.97%
1 month-6.31%
3 months-27.27%
6 months+19.53%
Current year-8.77%
1 week 1
Extreme 1
1.07
1 month 1
Extreme 1
1.14
Current year 0.69
Extreme 0.6866
1.5
1 year 0.69
Extreme 0.6866
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
17.6
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 06/03/2017
Director of Finance/CFO 56 01/08/2017
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 60 01/08/2006
Director/Board Member 72 01/02/2010
Chairman 75 11/02/2013
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/26 Tax

Chief Technology Officer

-4,518 0.0090%
02/04/26 Tax

Chief Executive Officer

9,938 0.0199%
02/04/26 Tax

Chief Technology Officer

2,444 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
+2.97%+0.97%-10.34%+107.96% 5.24Cr
-0.11%-3.69%+45.64%+129.39% 1,21600Cr
+1.12%+0.63%+47.04%+81.23% 66TCr
+0.80%-1.67%+32.38%+105.36% 51TCr
-0.36%-3.25%+47.17%+64.58% 38TCr
-0.13%-1.91%+70.97%+40.56% 36TCr
-0.78%-0.52%+30.57%+57.98% 31TCr
-0.80%-0.21%+8.54%+35.56% 29TCr
+0.26%-1.14%+45.97%+68.85% 25TCr
+0.34%-1.50%+36.24%+107.20% 21TCr
Average +0.30%-0.02%+35.42%+79.87% 41.88TCr
Weighted average by Cap. +0.04%+0.03%+42.41%+88.73%

Financials

2026 *2027 *
Net sales - 4L 4L 4L 3L 6L 4.2Cr 7L 44.16L 17.61L 2.24Cr 16.78L 16.42L 7.08Cr
Net income -1.56Cr -1.4Cr -1.28Cr -1.17Cr -2.2Cr -146.72Cr -2.27Cr -15Cr -6.15Cr -78Cr -5.86Cr -5.73Cr -247.15Cr -1.86Cr -1.67Cr -1.53Cr -1.39Cr -2.63Cr -175.16Cr -2.71Cr -18Cr -7.34Cr -93Cr -6.99Cr -6.84Cr -295.06Cr
Net Debt - -
Projected Income Statement - Annual - Talphera, Inc.
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
07/26/07 $1.040 +2.97% 46,471
05/26/05 $1.010 -3.81% 1,22,750
04/26/04 $1.050 +0.96% 92,482
03/26/03 $1.040 +2.97% 81,012
02/26/02 $1.010 -1.94% 55,862
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Talphera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.010USD
Average target price
3.125USD
Spread / Average Target
+209.41%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Talphera, Inc.
  1. Stock Market
  2. Stocks
  3. TLPH Stock